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anBACKGROUND Guidelines recommend long-term oral anticoagulation therapy for stroke prevention in patients with
atrial fibrillation (AF). Treatment discontinuation rates in vitamin K antagonist (VKA)-treated patients are high but may be
lower with non-VKA oral anticoagulant agents.
OBJECTIVES The goal of this study was to describe and explore predictors of dabigatran etexilate persistence in
patients with newly diagnosed AF over 2 years of follow-up.
METHODS Consecutive patients newly diagnosed with AF and $1 stroke risk factor were followed up for 2 years.
Dabigatran nonpersistence was defined as discontinuation of dabigatran for >30 days. A multivariable Cox regression
model included region as well as patient clinical and sociodemographic characteristics to explore predictors of
nonpersistence.
RESULTS Eligible patients (N ¼ 2,932) took $1 dabigatran dose; their mean age was 70.3  10.2 years, and 55.3% were
male. The 2-year probability of dabigatran persistence was 69.2%. Approximately 7% switched to a factor Xa inhibitor
and 6% to a VKA. Approximately one-third of dabigatran discontinuations were primarily due to serious or nonserious
adverse events. Patients from North America had the highest discontinuation risk, and Latin America had the lowest.
Minimally symptomatic or asymptomatic AF and permanent AF were associated with a lower risk for dabigatran
nonpersistence. Previous proton pump inhibitor use was associated with a higher risk for dabigatran nonpersistence.
CONCLUSIONS Probability of treatment persistence with dabigatran after 2 years was approximately 70%. Nearly
one-half of the patients who stopped dabigatran switched to another oral anticoagulant agent. Patients from
North America, and those with paroxysmal, persistent, or symptomatic AF, may be at a higher risk for
discontinuing dabigatran. (J Am Coll Cardiol 2017;70:1573–83) © 2017 The Authors. Published by Elsevier on behalf
of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license
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AND ACRONYMS
AE = adverse event
AF = atrial fibrillation
CI = confidence interval
HR = hazard ratio
NOAC = non–vitamin K oral
anticoagulant
OAC = oral anticoagulant
SAE = serious adverse event
TIA = transient ischemic attack
VKA = vitamin K antagonis
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1574A trial fibrillation (AF) is the mostcommon cardiac arrhythmia. It is awell-documented independent fac-
tor for ischemic stroke (1) that is associated
with considerable mortality and morbidity
(2–4). Current guidelines recommend long-
term oral anticoagulant (OAC) therapy for
stroke prevention in patients with AF who
are at risk for stroke (5). Until 2010, when
dabigatran etexilate, the first non–vitamin
K oral anticoagulant (NOAC) became avail-
able, vitamin K antagonists (VKAs) were
the standard anticoagulation therapy forpatients with AF. Although VKAs are effective in
preventing strokes, treatment discontinuation rates
are pronounced, with only 39% to 60% remaining
on VKA treatment after 1 year (6–8).
t
SEE PAGE 1584Several factors contribute to suboptimal treatment
adherence with VKAs. These factors include narrow
therapeutic windows that require frequent laboratory
monitoring, a variable dose–response relationship,
and interactions with food and medications for
comorbid conditions. These problems are diminished
with NOACs, which have been endorsed as a Class Ia
recommendation in the most recent guidelines for
managing patients with AF from the European Society
of Cardiology (5), as well as the American College of
Cardiology, the American Heart Association, and the
Heart Rhythm Society (9).
Medication adherence is defined as the accurate
intake of medications based on the dose, frequency,
and schedule prescribed (10). A closely related
concept, and the main target of the present investi-
gation, is medication persistence, defined as “theiener has received honoraria for participation in clinical trials, co
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tion of therapy” (11). The evidence evaluating the
persistence of VKA and NOAC therapies shows highly
variable reports of both persistence and medication
adherence, with generally better rates of adherence
and persistence with NOACs versus VKAs (12).
Adherence and, particularly, persistence are
expected to be affected by various factors, including
the incidence of adverse events (AEs). Nonetheless,
the reasons for treatment nonpersistence (used
interchangeably with treatment discontinuation) in
patients taking OACs for stroke prevention have not
been extensively described, especially in large
prospective patient cohorts.
We therefore sought to describe and assess reasons
for nonpersistence with treatment, including those
related to AEs. The present global, prospective cohort
study aimed to describe dabigatran nonpersistence,
with or without subsequent treatment with another
OAC, in patients receiving dabigatran and enrolled in
the GLORIA-AF (Global Registry on Long-term Oral
Anti-thrombotic Treatment in Patients with Atrial
Fibrillation) registry program between 2011 and 2014.
METHODS
The GLORIA-AF registry program enrolled consecu-
tive adult patients with AF seen in routine clinical
practice in 44 countries in 5 regions. Sources used to
identify a broad range of potential sites and physi-
cians included professional directories, referrals from
selected investigators and national coordinators, and
sites that had previously worked with the study
sponsor that funded the registry. Sites were selected
only on the basis of confirmation that they diagnosed
and followed up patients with AF; previous researchntribution to advisory boards, or oral presentations
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1575experience was not a prerequisite. Patients were
managed according to routine standard practice and
were not required to be prescribed any specific OAC
or any OAC at all.
Once dabigatran was approved for the indication of
stroke prevention in a respective country, countries
were immediately approached to start phase II. The
time to initiate the study in the countries varied and
depended on site identification, regulatory review
timelines, and ethical committee reviews at partici-
pating sites. Additional details on the design of the
GLORIA-AF program have been published previously
(13), and baseline characteristics of all eligible patients
enrolled in the phase II program have been described
elsewhere (14). In phase II of this study, follow-up
included only dabigatran-treated patients who were
recruited from various outpatient settings, including
university and community hospitals as well as
specialist and general practice offices. Patients with
newly diagnosed documented AF within 3 months of
the baseline visit and at least 1 risk factor for stroke
according to CHA2DS2-VASc (congestive heart failure,
hypertension, age $75 years, diabetes mellitus,
stroke/transient ischemic attack [TIA], vascular dis-
ease, age 65 to 74 years, sex category) criteria (15) were
eligible for inclusion into the registry program.
Patients with previous VKA therapy for >60 days, AF
due to generally reversible causes, and patients with
mechanical heart valves were excluded.
Patients who had important protocol violations
(e.g., lack of appropriate informed consent, partici-
pation in a clinical trial or international registry) or
data insufficiently cleaned (i.e., >2 open manual
queries) were excluded from analysis. Only patients
taking at least 1 dose of dabigatran and who had
follow-up data available were included.
Standard electronic case report forms were used to
record baseline characteristics, including stroke and
bleeding risk factors that constitute the CHA2DS2-
VASc (15) and HAS-BLED (hypertension, abnormal
renal/liver function, stroke, bleeding history or pre-
disposition, labile international normalized ratio,
elderly [age $65 years], drugs/alcohol concomitantly)
scores (16), respectively. Other characteristics
included were AF type (paroxysmal, persistent, or
permanent), AF-related symptoms based on the
European Heart Rhythm Association classification of
symptomatic, minimally symptomatic, or asymptom-
atic (17), antithrombotic treatment, medical history,
concomitant medications, and reimbursement status
of prescribed OAC. Start and stop dates of antith-
rombotic therapies and concomitant medications
were recorded by the treating physician based on in-
formation included in the patient source data records.THERAPY PERSISTENCE. Index therapy was the
treatment prescribed for long-term anticoagulation
therapy after the diagnosis of AF and recorded at the
baseline visit. At follow-up intervals (approximately
3, 6, 12, and 24 months after baseline), changes to
medical conditions, antithrombotic treatment
changes, and all serious adverse events (SAEs), in-
terventions, and adverse drug reactions, including
major and life-threatening bleeding events, were
recorded. The primary and mutually exclusive rea-
sons for discontinuing index dabigatran treatment
were also captured. Physicians could choose 1 reason
from a pre-specified list that included bleeding
events, alcohol intake, dementia, AEs, dyspepsia,
hypersensitivity, drug interactions, cost, or “other” if
the former options did not apply.
Therapy nonpersistence was defined in 2 ways to
characterize the probability of discontinuing the index
dabigatran therapy: 1) dabigatran nonpersistence—
patients who stop index dabigatran treatment
(for >30 days) during the follow-up period or switch to
another OAC within 30 days; or 2) dabigatran non-
persistence without switching—subgroup of patients
from the first group who stop index dabigatran treat-
ment (for >30 days) and do not start another OAC
within 30 days of dabigatran discontinuation.
STATISTICAL ANALYSIS. All data were analyzed
using SAS version 9.4 (SAS Institute, Inc., Cary, North
Carolina). Baseline data were summarized descrip-
tively overall, according to region, and for factors
related to treatment nonpersistence. Continuous
variables were reported as mean  SD, and categorical
variables were reported as absolute frequencies and
percentages. In addition, reasons for discontinuation
of dabigatran treatment at 2 years were summarized
descriptively.
Probabilities of dabigatran persistence were
evaluated by using a Kaplan-Meier time-to-event
analysis. Dose changes (e.g., lowering dose from
150 mg twice daily to 110 mg twice daily) were not
considered as switched treatment because dose
adjustments represented part of the antithrombotic
therapy management process.
Variables included in the Cox regression models to
evaluate risk factors associated with dabigatran
discontinuation included region, reimbursement
status of medication, and patient clinical and socio-
demographic characteristics. Patients were followed
up until study withdrawal, death, end of study, or
occurrence of dabigatran nonpersistence, whichever
came first.
To evaluate whether reclassification of patients
who switched treatments after a longer period after
dabigatran discontinuation (i.e., >30 days) would
FIGURE 1 Distribution of Patients Initiated on Dabigatran
Region 2
Europe
(n = 1502, 51.2%)
Austria, Bulgaria, Croatia, Czech Republic, Denmark,
Estonia, France, Germany, Greece, Ireland, Italy, Latvia,
The Netherlands, Norway, Portugal, Romania, Slovenia,
Spain, Sweden, Switzerland, UK
Region 3
North America
(n = 819, 27.9%)
Canada, USA
Region 1
Asia
(n = 363, 12.4%)
Mainland China,
Hong Kong,
Russia, Singapore,
South Korea, Taiwan
Region 5
Africa/
Middle East
(n = 54, 1.8%)
Lebanon, UAE
Region 4
Latin America
(n = 194, 6.6%)
Argentina, Brazil,
Colombia,
Mexico, Peru,
Venezuela
The heaviest concentration of patients was in Europe, followed by North America. UAE ¼ United Arab Emirates; UK ¼ United Kingdom; USA ¼ United States of America.
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1576change the results, an additional sensitivity analysis
was conducted, reclassifying the 28 patients who
switched to another OAC following the 30-day period
after dabigatran discontinuation.
RESULTS
A total of 3,002 patients were enrolled; 65 were
ineligible (2.2%), including 45 who did not meet
inclusion criteria or who met exclusion criteria, and
20 who did not meet data cleaning requirements. The
main reason for not meeting inclusion criteria was
absence of a new AF diagnosis (n ¼ 35). The
remainder (n ¼ 10) had AF with a reversible cause,
>60 days of warfarin treatment, or exclusionary valve
disease. Five patients (0.5%) were prescribed dabi-
gatran but were not treated, producing a total of 2,932
patients eligible for analysis who were prescribeddabigatran and took at least 1 dose. Most patients
were enrolled in Europe (51.2%), followed by North
America (27.9%); these were the regions in which
NOACs were first approved. In regions with later
NOAC approvals, fewer dabigatran-treated patients
were enrolled: Asia (12.4%), Latin America (6.6%),
and Africa and the Middle East (1.8%) (Figure 1).
PATIENT CHARACTERISTICS. Patients’ mean age
was 70.3  10.2 years, and slightly more than one-half
of patients were male. Approximately one-half had
paroxysmal AF (n ¼ 1,481; 50.5%), 1,063 (36.3%) had
persistent AF, and a minority had permanent AF
at the time of enrollment (n ¼ 388; 13.2%). Approxi-
mately one-quarter of the patient group had
symptomatic AF (26.5%), 46.5% reported minimally
symptomatic AF, and 27.0% reported asymptomatic
AF.
TABLE 1 Patient Characteristics and Predictors of Nonpersistence
Previous Stroke/TIA* PPI Use AF Type AF Symptoms
Total
(N ¼ 2,932)
Yes
(n ¼ 414)
No
(n ¼ 2,517)
Yes
(n ¼ 572)
No
(n ¼ 2,360)
Paroxysmal
or Persistent
(n ¼ 2,544)
Permanent
(n ¼ 388)
Minimally or
Asymptomatic
(n ¼ 2,155)
Symptomatic
(n ¼ 777)
Age, yrs 72.6  9.6 69.9  10.2 71.8  9.4 69.9  10.3 69.9  10.2 73.1  9.9 70.5  9.9 69.8  10.9 70.3  10.2
Age $75 yrs 184 (44.4) 891 (35.4) 235 (41.1) 841 (35.6) 890 (35.0) 186 (47.9) 780 (36.2) 296 (38.1) 1,076 (36.7)
BMI, kg/m2† 28.1  5.6 29.4  6.2 29.4  6.2 29.2  6.1 29.3  6.2 28.9  5.6 29.2  6.0 29.4  6.5 29.2  6.1
Male 224 (54.1) 1,395 (55.4) 286 (50.0) 1,334 (56.5) 1,410 (55.4) 210 (54.1) 1,237 (57.4) 383 (49.3) 1,620 (55.3)
MI* 45 (10.9) 203 (8.1) 62 (10.8) 186 (7.9) 215 (8.5) 33 (8.5) 191 (8.9) 57 (7.3) 248 (8.5)
Coronary artery disease‡ 102 (24.6) 489 (19.4) 138 (24.1) 454 (19.2) 517 (20.3) 75 (19.3) 441 (20.5) 151 (19.4) 592 (20.2)
Congestive heart failure§ 68 (16.4) 664 (26.4) 139 (24.3) 593 (25.1) 591 (23.2) 141 (36.3) 473 (21.9) 259 (33.3) 732 (25.0)
History of hypertensionk 325 (78.5) 1,896 (78.9) 466 (81.5) 1,846 (78.2) 2,003 (78.7) 309 (79.6) 1,699 (78.8) 613 (78.9) 2,312 (78.9)
Diabetes mellitus 93 (22.5) 572 (22.7) 157 (27.4) 508 (21.5) 580 (22.8) 85 (21.9) 503 (23.3) 162 (20.8) 665 (22.7)
CHA2DS2-VASc risk score 5.0  1.3 2.9  1.2 3.6  1.5 3.1  1.4 3.2  1.4 3.6  1.4 3.2  1.4 3.3  1.4 3.2  1.4
Previous bleeding event¶ 41 (9.9) 106 (4.2) 48 (8.4) 99 (4.2) 133 (5.2) 14 (3.6) 111 (5.2) 36 (4.6) 147 (5.0)
HAS-BLED score# 2.0  0.9 1.1  0.7 1.4  0.9 1.2  0.8 1.2  0.8 1.3  0.8 1.3  0.9 1.2  0.8 1.2  0.8
Renal impairment** 1 (0.2) 11 (0.4) 1 (0.2) 11 (0.5) 10 (0.4) 2 (0.5) 9 (0.4) 3 (0.4) 12 (0.4)
Physician specialty††
Cardiology 341 (82.4) 2,328 (92.5) 506 (88.5) 2,164 (91.7) 2,325 (91.4) 345 (88.9) 1,934 (89.7) 736 (94.7) 2,670 (91.1)
General practitioner
or geriatrician
12 (2.9) 92 (3.7) 24 (4.2) 80 (3.4) 93 (3.7) 11 (2.8) 83 (3.9) 21 (2.7) 104 (3.5)
Internist 6 (1.4) 57 (2.3) 12 (2.1) 51 (2.2) 43 (1.7) 20 (5.2) 54 (2.5) 9 (1.2) 63 (2.1)
Neurologist 46 (11.1) 2 (0.1) 33 (1.4) 2 (0.1) 45 (1.8) 3 (0.8) 47 (2.2) 1 (0.1) 48 (1.6)
Other 9 (2.2) 36 (1.4) 13 (2.3) 32 (1.4) 37 (1.5) 8 (2.1) 35 (1.6) 10 (1.3) 47 (1.6)
Values are mean  SD or n (%), with percentages expressed as the number of patients with the condition present divided by the total number of patients with data available. *Unknown in 1 patient.
†Unknown or missing in 20 patients. ‡Unknown in 74 patients. §Unknown in 32 patients. kUnknown in 7 patients. ¶Unknown in 52 patients. #Unknown or missing in 300 patients. **Unknown in 26 patients.
††Unknown in 2 patients.
AF ¼ atrial fibrillation; BMI ¼ body mass index; CHA2DS2-VASc ¼ congestive heart failure, hypertension, age $75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65 to 74
years, sex category; HAS-BLED ¼ hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly (age $65 years), drugs/alcohol
concomitantly; MI ¼ myocardial infarction; PPI ¼ proton pump inhibitor; TIA ¼ transient ischemic attack.
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1577About one-third of patients were $75 years of age,
and most were considered at high risk for stroke
(CHA2DS2-VASc score $2 in 88.2% of patients). The
majority of patients were considered at low risk for
bleeding (HAS-BLED score <3 in 83.5% of patients),
and only 5.0% had a previous bleeding event. The
majority of patients had a history of hypertension,
and 1 in 5 had coronary artery disease. The baseline
characteristics of patients according to region and
other risk factors for discontinuation are shown in
Tables 1 and 2.
OVERALL TREATMENT PERSISTENCE. The probabil-
ity of dabigatran treatment persistence was 76.6% at
1 year and 69.2% at 2 years. This finding was even
higher when considering those who remained on
dabigatran or discontinued dabigatran to start
another OAC within 30 days (i.e., 87.7% at 1 year and
84.1% at 2 years) (Central Illustration).
At the end of follow-up, 828 patients had dis-
continued dabigatran. Of the total 2,932 dabigatran-
treated patients, 1,859 remained on dabigatran
(63.4%) until study termination, 438 (14.9%)
discontinued treatment without switching to another
OAC, and 390 (13.3%) switched to another OAC.Baseline characteristics of the patients who remained
on dabigatran, discontinued with switching to
another OAC, or discontinued without switching are
shown in Online Table 1. There were 214 patients
(7.3%) who switched to a factor Xa inhibitor, and 176
patients (6.0%) who switched to a VKA; 128 patients
(4.4%) were lost to follow-up, and 117 (4.0%) died
before the end of follow-up.
REASONS FOR NONPERSISTENCE AT 2 YEARS. Primary
reasons given for discontinuing dabigatran treatment
are presented in Table 3. Among patients discontinu-
ing dabigatran (n ¼ 828), 66 (8.0%) stopped primarily
due to dyspepsia and approximately 25% stopped
primarily due to other AEs (64 [7.7%] SAEs; 62 [7.5%]
nonserious AEs; 58 [7.0%] bleeding events; 22 [2.7%]
hypersensitivity to agent; 2 [0.2%] bruising; and 2
[0.2%] due to concomitant medication interactions).
The majority of respondents (59.8%) cited “other”
(reason not otherwise specified) as the primary reason
for discontinuation of dabigatran. Upon further
investigation of the proportion of patients who dis-
continued treatment citing AEs as the primary reason
(including bleeding, bruising, dyspepsia, hypersensi-
tivity or interactions with the agent, or other AEs or
TABLE 2 Patient Characteristics According to Geographic Region
Region
Total
(N ¼ 2,932)
Europe
(n ¼ 1,502)
North America
(n ¼ 819)
Asia
(n ¼ 363)
Latin America
(n ¼ 194)
Middle East or Africa
(n ¼ 54)
Age, yrs 70.7  10.0 70.8  10.2 67.1  10.6 71.3  10.1 70.4  9.5 70.3  10.2
Age $75 yrs 574 (38.2) 315 (38.5) 88 (24.2) 81 (41.8) 18 (33.3) 1,076 (36.7)
BMI, kg/m2* 28.6  5.4 30.9  7.3 28.3  5.7 28.3  5.1 29.6  6.1 29.2  6.1
Male 811 (54.0) 484 (59.1) 195 (53.7) 109 (56.2) 21 (38.9) 1,620 (55.3)
MI† 113 (7.5) 86 (10.5) 31 (8.5) 14 (7.2) 4 (7.4) 248 (8.5)
Coronary artery disease‡ 237 (15.8) 220 (26.9) 101 (27.8) 21 (10.8) 13 (24.1) 592 (20.2)
Congestive heart failure§ 396 (26.4) 132 (16.1) 139 (38.3) 57 (29.4) 8 (14.8) 732 (25.0)
History of hypertensionk 1,145 (76.2) 665 (81.2) 303 (83.5) 151 (77.8) 48 (88.9) 2,312 (78.9)
Diabetes mellitus 318 (21.2) 211 (25.8) 81 (22.3) 36 (18.6) 19 (35.2) 665 (22.7)
CHA2DS2-VASc risk score 3.2  1.4 3.2  1.5 3.2  1.4 3.3  1.4 3.6  1.4 3.2  1.4
Previous bleeding event¶ 57 (3.8) 64 (7.8) 16 (4.4) 9 (4.6) 1 (1.9) 147 (5.0)
HAS-BLED score# 1.2  0.8 1.4  0.9 1.1  0.8 1.2  0.8 1.2  0.7 1.2  0.8
Renal impairment** 4 (0.3) 6 (0.7) 0 (0.0) 2 (1.0) 0 (0.0) 12 (0.4)
Physician specialty††
Cardiology 1,447 (96.3) 661 (80.7) 334 (92.0) 175 (90.2) 54 (100.0) 2,670 (91.1)
General practitioner or geriatrician 11 (0.7) 65 (7.9) 15 (4.1) 13 (6.7) 0 (0.0) 104 (3.5)
Internist 10 (0.7) 47 (5.7) 0 (0.0) 6 (3.1) 0 (0.0) 63 (2.1)
Neurologist 8 (0.5) 40 (4.9) 0 (0.0) 0 (0.0) 0 (0.0) 48 (1.6)
Other 25 (1.7) 6 (0.7) 14 (3.9) 0 (0.0) 0 (0.0) 47 (1.6)
Values are mean  SD or n (%), with percentages expressed as the number of patients with the condition present divided by the total number of patients with data available.
*Unknown or missing in 20 patients. †Unknown in 1 patient. ‡Unknown in 74 patients. §Unknown in 32 patients. kUnknown in 7 patients. ¶Unknown in 52 patients. #Unknown
or missing in 300 patients. **Unknown in 26 patients. ††Unknown in 2 patients.
Abbreviations as in Table 1.
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(58.3%) occurred in the first 6 months. Most individual
AEs were reported in the first 6 months, including
the following: bleeding events or bruising, 65.0%;
dyspepsia, 57.8%; hypersensitivity to agents, 72.7%;
and general adverse drug reactions, 62.9%. For SAEs
that were not necessarily related to dabigatran, 43.8%
were reported in the first 6 months.
Overall, primary discontinuation due to cost of
treatment was reported relatively infrequently,
with <3% of all primary reasons for discontinuation
cited due to cost (Table 3). When evaluating the main
reasons for discontinuation in North America
compared with Europe, for example, where we might
expect higher rates of reimbursement, the proportion
of primary reasons for discontinuation due to cost
were not markedly different (North America, 1.0%;
Asia, 4.0%; Europe, 3.1%; and Latin America, 0.0%).
Upon further investigation of patients who dis-
continued treatment with a primary reason docu-
mented as “other,” only a small proportion of the
patients overall (8.1%) had adverse drug reactions or
serious AEs that were reported within 30 days before
discontinuation (not necessarily related to treatment
discontinuation). Furthermore, there were no
thromboembolic events observed within 30 days
before discontinuation in this group of patients.PREDICTORS OF TREATMENT PERSISTENCE. Factors
associated with dabigatran nonpersistence were
region, type of AF, type of site, categorization of AF,
physician specialty, and previous proton pump
inhibitor use (Table 4). In particular, patients in North
America were at higher risk of dabigatran discontin-
uation (hazard ratio [HR]: 1.66; 95% confidence
interval [CI]: 1.35 to 2.04) compared with those in
Europe, and patients in Latin America were at lower
risk (HR: 0.61; 95% CI: 0.40 to 0.90). Patients with
asymptomatic or minimally symptomatic AF were
more likely to be persistent compared with symp-
tomatic patients. Those with permanent AF were
similarly less at risk for nonpersistence versus those
with paroxysmal or persistent AF, as were patients
followed up by a primary care physician compared
with those followed up at a community hospital.
Previous proton pump inhibitor use was predictive
of dabigatran nonpersistence (HR: 1.26; 95% CI: 1.04
to 1.51).
Patients who were enrolled at a specialist’s office
had a similar risk for discontinuation compared with
those at a community hospital (HR: 0.99; 95% CI: 0.80
to 1.23); however, patients enrolled at a university
hospital did not seem to be markedly at higher risk of
discontinuation (Table 4). Other factors included in
the model are shown in Online Table 2.
CENTRAL ILLUSTRATION Therapy Persistence With DE: Kaplan-Meier Curve of Time to
Treatment Discontinuation Over 2 Years
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2,932 2,696 2,519 2,405 2,320 2,231 2,180 2,118 1,668
DE persistence or switch to another OAC
Paquette, M. et al. J Am Coll Cardiol. 2017;70(13):1573–83.
This study explored predictors of dabigatran etexilate (DE) persistence in patients with newly diagnosed atrial fibrillation over 2 years of
follow-up. The probability of dabigatran treatment persistence was 76.6% at 1 year and 69.2% at 2 years. All eligible patients are rep-
resented, excluding those prescribed but not treated with DE. *Persistence was even higher in those patients who remained on DE or switched
to another oral anticoagulant (OAC). †Patients remaining on DE are considered persistent, and patients who switch or discontinue are
considered nonpersistent.
TABLE 3 Reasons for Discontinuation of DE Treatment at 2 Years
Patients Who
Discontinued DE and
Did Not Use Another
OAC After Stopping
(n ¼ 438)
Patients Who Switched
From DE to Another
OAC Within 30 Days*
(n ¼ 390)
Total
(N ¼ 828)
Other† 285 (65.1) 210 (53.8) 495 (59.8)
Dyspepsia 10 (2.3) 56 (14.4) 66 (8.0)
Adverse events‡ 27 (6.2) 35 (9.0) 62 (7.5)
Serious adverse events‡ 43 (9.8) 21 (5.4) 64 (7.7)
Bleeding events 40 (9.1) 18 (4.6) 58 (7.0)
Hypersensitivity to agent 6 (1.4) 16 (4.1) 22 (2.7)
Cost of treatment 10 (2.3) 9 (2.3) 19 (2.3)
Social reason (drug, alcohol
abuse)
7 (1.6) 6 (1.5) 13 (1.6)
Bruising 0 (0.0) 2 (0.5) 2 (0.2)
Bridging therapy start 7 (1.6) 2 (0.5) 9 (1.1)
Dementia 2 (0.5) 2 (0.5) 4 (0.5)
Severe interaction with
concomitant medication
1 (0.2) 1 (0.3) 2 (0.2)
Values are n (%). *Data are missing for 12 patients who switched from DE to another OAC. †Reason was not
specified. ‡Does not include adverse events listed in the table.
DE ¼ dabigatran etexilate; OAC ¼ oral anticoagulant.
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1579PATIENTS WITHOUT SWITCH TO ANOTHER OAC. Region
was the strongest predictor of nonpersistence
without switch, with North America having the
greatest risk of dabigatran nonpersistence. In this
subgroup analysis, patients in Asia had similar rates
of discontinuation as Europe but were at higher risk
of discontinuing without switching (HR: 1.64; 95% CI:
1.20 to 2.21) (Table 4). Latin America and the Middle
East (including South Africa) had the lowest risk of
dabigatran nonpersistence in this subgroup versus
Europe. The main clinical variables associated with a
lower risk of dabigatran nonpersistence without
switch in the Cox model were previous stroke or TIA
and permanent AF versus paroxysmal or persistent
AF. Previous myocardial infarction was associated
with a higher risk of nonpersistence, as was treatment
at a university hospital compared with a community
hospital. Other factors included in the model are
shown in Online Table 2.
The sensitivity analysis considering patients as
switchers if they had started another OAC after
TABLE 4 Main Predictors of DE Nonpersistence
N
DE Nonpersistent
Patients
(n ¼ 828)
Adjusted HR*
(95% CI)
DE Nonpersistent Patients
Without Subsequent OAC†
(n ¼ 438)
Adjusted HR*
(95% CI)
Region
Europe 1,502 383 (25.5) Ref. 187 (12.5) Ref.
North America 819 303 (37.0) 1.66 (1.35–2.04) 156 (19.0) 1.53 (1.15–2.03)
Asia 363 101 (27.8) 1.18 (0.92–1.50) 72 (19.8) 1.64 (1.20–2.21)
Latin America 194 30 (15.5) 0.61 (0.40–0.90) 17 (8.8) 0.62 (0.35–1.03)
Africa or Middle East 54 11 (20.4) 0.72 (0.36–1.27) 6 (11.1) 0.86 (0.33–1.84)
Categorization of AF
Symptomatic 777 248 (31.9) Ref. 132 (17.0) Ref.
Minimally symptomatic or
asymptomatic
2,155 580 (26.9) 0.78 (0.66–0.91) 306 (14.2) 0.84 (0.67–1.05)
Previous TIA or stroke
No or missing 2,518 726 (28.8) Ref. 398 (15.8) Ref.
Yes 414 102 (24.6) 0.84 (0.66–1.06) 40 (9.7) 0.66 (0.46–0.93)
Type of AF
Paroxysmal or persistent AF 2,544 749 (29.4) Ref. 401 (15.8) Ref.
Permanent AF 388 79 (20.4) 0.73 (0.56–0.93) 37 (9.5) 0.66 (0.46–0.93)
PPIs
No 2,360 640 (27.1) Ref. 350 (14.8) Ref.
Yes 572 188 (32.9) 1.26 (1.04–1.51) 88 (15.4) 1.04 (0.80–1.36)
Type of site
Community hospital 866 220 (25.4) Ref. 105 (12.1) Ref.
University hospital 635 187 (29.4) 1.16 (0.94–1.44) 100 (15.7) 1.35 (1.00–1.81)
Specialist office 1,065 332 (31.2) 0.99 (0.80–1.23) 182 (17.1) 1.31 (0.97–1.76)
GP or primary care 226 51 (22.6) 0.71 (0.50–0.98) 31 (13.7) 1.10 (0.70–1.69)
Outpatient health care or
anticoagulation clinic
117 31 (26.5) 0.88 (0.57–1.31) 17 (14.5) 0.89 (0.49–1.51)
MI
No or missing 2,684 748 (27.9) Ref. 395 (14.7) Ref.
Yes 248 80 (32.3) 1.10 (0.81–1.47) 43 (17.3) 1.43 (0.95–2.11)
CHA2DS2-VASc score class
High (score $2) 2,587 715 (27.6) Ref. 365 (14.1) Ref.
Moderate (score ¼ 1) 345 113 (32.8) 1.13 (0.88–1.45) 73 (21.2) 1.31 (0.94–1.80)
Age class
<75 yrs 1,856 536 (28.9) Ref. 303 (16.3) Ref.
$75 yrs 1,076 292 (27.1) 0.95 (0.80–1.12) 135 (12.5) 0.84 (0.66–1.06)
Congestive heart failure
No or missing 2,200 639 (29.0) Ref. 325 (14.8) Ref.
Yes 732 189 (25.8) 0.96 (0.80–1.15) 113 (15.4) 1.16 (0.92–1.46)
History of hypertension
No or missing 620 183 (29.5) Ref. 93 (15.0) Ref.
Yes 2,412 645 (26.7) 0.90 (0.75–1.08) 345 (14.3) 1.01 (0.79–1.31)
Coronary artery disease
No or missing 2,340 646 (27.6) Ref. 352 (15.0) Ref.
Yes 592 182 (30.7) 1.05 (0.84–1.30) 86 (14.5) 0.79 (0.57–1.06)
Continued on the next page
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identified) yielded similar results.
DISCUSSION
In this prospective assessment of clinical practice
data from a global registry program, overall dabiga-
tran persistence in an incident AF population washigh, with the probability of remaining on dabigatran
treatment after 1 year at approximately 75% and
approximately 70% after 2 years. Of clinical impor-
tance, about one-half of those patients who
discontinued treatment during follow-up did not
start another OAC within 30 days, leaving patients at
risk for stroke at least in the early period after initial
discontinuation. To our knowledge, this trial was the
TABLE 4 Continued
N
DE Nonpersistent
Patients
(n ¼ 828)
Adjusted HR*
(95% CI)
DE Nonpersistent Patients
Without Subsequent OAC†
(n ¼ 438)
Adjusted HR*
(95% CI)
Chronic gastrointestinal diseases
No or missing 2,526 690 (27.3) Ref. 359 (14.2) Ref.
Yes 406 138 (34.0) 1.08 (0.87–1.33) 79 (19.5) 1.25 (0.94–1.64)
Medical treatment reimbursed by
Statutory or federal insurance 1,999 559 (28.0) Ref. 283 (14.2) Ref.
Private insurance 578 183 (31.7) 1.06 (0.88–1.29) 96 (16.6) 1.06 (0.81–1.38)
Self-pay, no coverage, or unknown 355 86 (24.2) 1.01 (0.78-1.28) 59 (16.6) 1.24 (0.90–1.66)
BMI, kg/m2
<30 1,832 518 (28.3) Ref. 279 (15.2) Ref.
$30 1,080 307 (28.4) 0.95 (0.81–1.12) 158 (14.6) 0.84 (0.67–1.04)
DE monotherapy vs. combination
DE monotherapy 2,539 704 (27.7) Ref. 360 (14.2) Ref.
DE combination 393 124 (31.6) 1.00 (0.80–1.25) 78 (19.8) 1.27 (0.95–1.70)
Values are n or n (%), unless otherwise indicated. A total of 333 patients from other types of site or having missing values for BMI or HAS-BLED score were excluded from the
multivariable analyses. *Adjusted HRs were estimated from a multivariable Cox model including all variables listed in this table and in Online Table 2. †Represents patients who
discontinue DE but do not start another OAC within 30 days.
CI ¼ confidence interval; GP ¼ general practice; HR ¼ hazard ratio; Ref. ¼ reference group; other abbreviations as in Tables 1 and 3.
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regional differences in persistence patterns, specif-
ically with an NOAC (dabigatran).
PUBLISHED STUDIES OF OAC PERSISTENCE. Previ-
ous evaluations of persistence have consistently
shown relatively poor persistence with warfarin
treatment, with 1-year discontinuation rates ranging
from approximately 25% (18,19) to >60% (7). Some
studies defined discontinuation as a treatment gap of
45 to 60 days, a definition less stringent than the one
used here (30 days). Comparing persistence across
studies is difficult, because even those focused on the
same OAC may differ with respect to the patient
populations, study designs, and definitions of
nonpersistence.
In XANTUS (Xarelto for Prevention of Stroke in
Patients with Atrial Fibrillation), another prospective
registry of patients treated with the NOAC rivarox-
aban, persistence over a 1-year period was high, with
discontinuation rates of approximately 20% (20). A
database study by Jackevicius et al. (21), which
evaluated NOAC treatment persistence, defined
nonpersistence as >14-day gaps between pre-
scriptions. Persistence was described at 6-month
follow-up, and approximately one-third of patients
were nonpersistent to dabigatran and rivaroxaban.
This population was considerably older, had a higher
prevalence of comorbidity, and did not represent an
incident AF population, with just over one-half of
the population having a history of warfarin use.Importantly, in this study, the risk of stroke, TIA, or
death was significantly higher in those nonpersistent
to dabigatran or rivaroxaban compared with those
who were persistent.
Better persistence with NOACs may stem from
better overall acceptance of NOAC therapies, result-
ing from a lower burden of monitoring and fewer food
and drug interactions compared with VKAs.
Conversely, it also could be posited that persistence
with NOACs could be less favorable due to fewer
overall visits with health care providers, resulting in
fewer opportunities to have the importance of treat-
ment persistence emphasized.
It has been shown that risk of discontinuation is
highest in the early period after treatment initiation
(6 months to 1 year), after which discontinuation
rates level off or decline more gradually (18,19,22).
Therefore, studies evaluating treatment persistence
for only limited periods after treatment initiation
might not accurately predict the discontinuation
rates over the long term. Persistence should thus be
measured directly for at least a period of 1 year or
longer where possible.
REASONS FOR DISCONTINUATION. The data from
this analysis suggest that the reasons for discontinu-
ation of treatment are complex and might not be
fully explained solely by examining adverse drug
reactions such as bleeding or other AEs. Approxi-
mately one-third of all reasons for primary dabigatran
discontinuation were cited as due to an AE or SAE.
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discontinuation or switch were “other”; that is, not
related to AEs or SAEs or to AEs associated with OAC
treatment, such as bleeding or dyspepsia. A separate
analysis in this group of patients found only a small
number of AEs reported within 30 days before
discontinuation, confirming that the responses indi-
cated under the other reasons for discontinuation did
not seem to include adverse events.
There might be an influence of patient or physician
preference, potentially a higher perceived risk for
outcomes that prompted changes in treatment, or
other factors that were not directly explored. Indeed,
in a review of adherence to NOACs, the importance of
the patient’s perspective was emphasized for making
decisions around anticoagulant choice (23), and these
preferences could also have strong implications for
treatment persistence or switching to an alternative
OAC.
PREDICTORS OF TREATMENT DISCONTINUATION. In the
present study, clinical factors predicted which
patients were most likely to discontinue dabigatran
treatment, with or without switching to an alternative
OAC. The multivariable analyses showed that factors
such as region (North America) and previous proton
pump inhibitor use might be associated with dabiga-
tran nonpersistence. Measures that might be markers
of disease severity, such as permanent AF, were
associated with persistence.
This pattern was also seen in predictors of the
subgroup that discontinued dabigatran but did not
switch to another OAC within 30 days. In this group,
which better reflects those who are at risk of
complications stemming from lack of prophylaxis, the
factors associated with a lower risk of nonpersistence
included permanent AF (vs. paroxysmal or persistent
AF) and previous stroke or TIA. Previous myocardial
infarction was also associated with a higher risk
of nonpersistence. Patients from Asia and North
America had a higher risk of nonpersistence with
dabigatran compared with patients from Europe.
Treatment-related AEs, such as dyspepsia or
hypersensitivity reactions, were a more prevalent
reason for switching than for discontinuing treat-
ment. In cases of discontinuation without switching,
SAEs and bleeding events were more often cited
compared with those who switched, suggesting that
patients who have more serious OAC-related side
effects would more often remain untreated.
Clinical factors such as permanent AF, previous
stroke, and low symptom burden, all associated with
treatment persistence, might be important clinical
surrogates for disease severity. Physicians mightprovide more vigorous reminders or directives
regarding the importance of OACs in stroke preven-
tion for patients with these markers, or patients
themselves could be more committed to remaining on
treatment after experiencing a previous stroke or TIA
or experiencing more longstanding episodes of AF.
Longer episodes of AF duration could, indeed, relate
to the perception that a higher AF burden increases
stroke risk and, thus, influence patients to remain on
OAC therapy.
STUDY LIMITATIONS. To our knowledge, this study
was the first prospective study to describe regional
differences in persistence patterns. These regional
differences might be secondary to differences in
clinical standards, patient preferences, or patient
management. Of note, the predictors of increased risk
for treatment nonpersistence seemed to relate to
factors associated with lower disease severity and to
geographic differences.
Our study had several limitations that should be
noted. Patients consented to participate in the study,
and physicians were aware that persistence to treat-
ment would be recorded, potentially modifying be-
haviors (i.e., the Hawthorne effect) (24). There could
be increased attention from the treating physician,
influencing patients to remain on treatment. Also,
patients more likely to have good adherence might
agree to participate in a registry, resulting in higher
overall rates of treatment persistence.
Patients were not followed up in the VKA group in
this phase of the registry, which limited our ability to
make comparisons. Another limitation was that only
1 primary reason was ascertained for treatment
discontinuation. Furthermore, for a large proportion
of patients, no specific information on the reason for
discontinuation was available, as the “other” cate-
gory of reason for discontinuation was chosen
without an option for additional free field text.
Finally, phase II started later in certain regions (Latin
America, Africa and the Middle East), which are
therefore less well represented in the data.
CONCLUSIONS
In this analysis of patients newly diagnosed with AF,
we found evidence for long-term persistence with
dabigatran, with an approximately 30% probability of
discontinuing index dabigatran treatment after
2 years. About one-half of those who discontinued
dabigatran received another OAC within 30 days.
Most of the primary reasons noted for treatment
discontinuation did not directly relate to AEs, which
implies that other factors, such as perceived
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND PROCEDURAL
SKILLS: Persistence with OAC therapy in patients with AF is a
barrier to achieving optimum clinical outcomes. Long-term
persistence with dabigatran was high, with approximately 70%
remaining on treatment after 2 years. Factors associated with
discontinuation of dabigatran included region (North America
and Asia with the highest risk compared with Europe), high
AF symptom burden, paroxysmal or persistent rather than
permanent AF, previous use of proton pump inhibitor inhibitors,
and absence of previous stroke or TIA.
TRANSLATIONAL OUTLOOK: Future studies should evaluate
reasons for discontinuing OAC therapy over time in patients with
AF to develop interventions that improve treatment persistence.
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1583thromboembolic and bleeding risks or patient pref-
erences, might play an important role in decisions to
persist with treatment. Surrogate markers of AF
severity, such as permanent AF, were associated with
a lower risk of treatment discontinuation, suggesting
that patients without these characteristics might be
an important group to target to increase treatment
persistence.
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